Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A market commentary published July 15 pointed to similar ominous technical setups in Pfizer and Gilead Sciences, but argued the selloffs reflect different underlying concerns. The piece frames the gap between market anxiety and analyst “fair value” as the core tension for investors.
THE APEX TIMES
THE APEX TIMES
Ahead of the opening bell on Wednesday, July 15, analysts are looking for Johnson & Johnson to post quarterly earnings of $2.85 per share, compared with $2.77 per share a year earlier. A Yahoo Finance piece also framed the event as an opportunity for income-seeking investors, though it did not provide details in the information available here.
THE APEX TIMES
A full-year outlook lift tied to stronger-than-expected second-quarter results was not enough to calm concerns around weakness in Stelara sales, even as oncology performance helped offset the decline.
THE APEX TIMES
The healthcare conglomerate reported results that beat expectations and increased its full-year guidance, even as JNJ stock slipped in early trading.
THE APEX TIMES
AdvanCell Pty, a biotechnology company supported by Eli Lilly and Co., has secured $315 million in new financing to advance an experimental cancer therapy, highlighting continued investor appetite for early-stage oncology science.
THE APEX TIMES
A fresh set of valuation assumptions has nudged the estimated fair value of HCA Healthcare down to about $490 per share from roughly $504, with the adjustment tied to concerns that health policy risks could weigh on the company’s outlook.
THE APEX TIMES
The company’s latest results beat Wall Street forecasts, yet investors sent Johnson & Johnson’s stock lower premarket as the market weighed what comes next.
THE APEX TIMES
The company said its latest quarter showed continued momentum from its product pipeline, and it increased its 2026 guidance.
THE APEX TIMES
The New Brunswick, New Jersey-based healthcare company’s board set the cash dividend at $1.34 per common share for the July-to-September quarter, a routine shareholder payout that outlines continued capital return.
